NCT00077454View on ClinicalTrials.gov

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

September 30, 2007

Conditions
Previously Treated Childhood RhabdomyosarcomaRecurrent Childhood Brain TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood MedulloblastomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent NeuroblastomaRecurrent Osteosarcoma
Interventions
DRUG

erlotinib hydrochloride

Given orally (PO)

DRUG

temozolomide

Given PO

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

91006-3776

COG Phase I Consortium, Arcadia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00077454 - Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter